Beyond anticholinergic effects: A case of trihexyphenidyl-induced bradycardia
Soumi Kundu1, R G Medhagopal2, Sarthak Das1
1Department of Pediatrics, All India Institute of Medical Sciences, Deoghar, Jharkhand, India.
Abstract:
Anticholinergic drugs are extensively employed in clinical settings, with their side effects well-documented. However, paradoxical bradycardia due to trihexyphenidyl hydrochloride, an anticholinergic agent, is an infrequent and underreported phenomenon. This may be attributed to a lack of vigilant monitoring in patients undergoing therapy. Here, we present the case of a 12-year-old girl who developed sinus bradycardia following the administration of trihexyphenidyl. The heart rate normalized upon drug discontinuation. This report emphasizes the need for thorough cardiac monitoring, including baseline heart rate, Electrocardiogram (ECG), and electrolyte evaluation, before initiating therapy to prevent adverse outcomes.
More Related Videos
08:56Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
Published on: September 24, 2021
06:25Paw-Print Analysis of Contrast-Enhanced Recordings PrAnCER: A Low-Cost, Open-Access Automated Gait Analysis System for Assessing Motor Deficits
Published on: August 12, 2019
Related Concept Videos
Decreased pulse rate
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Dysrhythmias IV: Characteristics of Bradyarrhythmias
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
